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Abstract
Drug Resistance is a major challenge in the control of Tuberculosis which itself re‐
mains a global public health problem. Resistance is commonly encountered as MDR
TB but a subset, XDR TB which has about a comparatively fivefold increase in mortal‐
ity is now identified in 84 countries worldwide and increasing rates are currently re‐
ported from 65 countries. The actual burden of MDR TB is unknown though estimates
have been made based on notification of cases which are usually underreported. More
so there is under diagnosis in non HIV immune suppressed adults and pediatric pop‐
ulations largely due to lack of readily accessible diagnostic tools. In some case series,
MDR TB has been found occurring mostly in newly diagnosed patients or relapse cas‐
es after previous cure and completion of treatment rather than in patients with im‐
properly treated disease. Clinical and laboratory monitoring once therapy has been
instituted have also been a daunting task both from institutional and patient points of
view. The impact of these factors are highlighted and discussed as the world moves
towards attainment of the 2015 global target to halve TB prevalence and death rates
within the context of Millennium Development Goals (MDGs).
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1. Introduction
The man who moves a mountain begins by carrying away small stones – Confucius.
Drug resistance is a major challenge in the control of Tuberculosis (TB), which itself remains
a global public health problem. Resistance is commonly encountered as Multidrug-Resistant
Tuberculosis (MDR TB), but a subset, Extensively Drug-Resistant Tuberculosis (XDR TB),
which has about a comparatively fivefold increase in mortality, is now identified in 84
countries worldwide and increasing rates are currently reported from 65 countries. The World
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Health Organization (WHO) has designated 22 countries of the world as high-burden countries
for Tuberculosis (HBCTB) and 27 as high-burden countries for multidrug-resistant Tubercu‐
losis (HBC MDR TB), making a total of 36 countries in either of these categories [1]. The latter
are countries where at least 4,000 cases of MDR TB are identified per year and/or at least 10%
of newly registered TB cases are MDR TB.
MDR TB and XDR TB epidemics are largely driven by transmission and are mainly found in
new cases and patients with TB relapse [2]. Since 1994, WHO has been receiving and analyzing
data on anti-TB drug resistance from countries via its Drug Resistance Surveillance Project,
which depends on continuous data based on rapid molecular diagnostics and drug sensitivity
testing (DST). However, neither is widely or routinely available due to prohibitive costs
involved, especially in low- and middle-income economies that are also high-burden countries.
In these low- and middle-income high TB burden countries, cases of MDR TB are identified
mainly through special surveys rather than continuous surveillance reporting. In 2013, only
11 of the 36 HBCTB/HBC MDRTB had up-to-date data through these drug-resistance surveys.
From these surveys it is clearly understood that the MDR TB burdens attributed to these
countries are only estimates based on notification of cases which in most countries is incom‐
plete and as such may only be the tip of the iceberg (Figures 1 & 2).
Despite these shortfalls in the determination of exact incidences, especially where TB burden
is highest, there have been recent global efforts to bridge the gap between diagnosis and
appropriate therapy with second- and third-line drugs. Treatment after diagnosis of MDR TB
and follow-up of confirmed cases is however bedeviled with unavailability of human resour‐
ces, accessibility to second-line drugs in high MDR TB areas, and logistics. Global treatment
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Figure 1. Percentage of new TB cases with MDR-TB (Adapted from WHO Global TB Report, 2014)
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targets have not been met. but there are concerted efforts to achieve them through restructuring
of programs and Programmatic Management of Drug-Resistant TB (PMDT).
The key to overcoming MDR TB and XDR TB will eventually lie in the balance between prompt
diagnosis and treatment of cases on one hand and prevention of transmission of drug-resistant
bacilli to vulnerable populations with whom they are in contact on the other. Particular
attention needs to be given to unrecognized groups: the pediatric patients in whom a high
degree of clinical skill must be displayed to ensure prompt laboratory diagnosis and the health
care workers whose infection can be prevented through deliberate control methods.
2. Epidemiology of MDR TB
It is estimated that more than 90% of new TB cases and death occur in the high TB burden
developing countries [3]. Multidrug anti-tuberculous therapy had been found effective when
using the Directly Observed Therapy Short Course (DOTS) strategy to improve compliance to
treatment of TB. With the emergence of MDR TB, the DOTS strategy was expanded to
accommodate second-line drugs in the Directly Observed Therapy short course with MDR
diagnosis, management, and treatment (DOTS PLUS) strategy. Treatment failure, however,
can still occur leading to relapse and development of drug-resistant TB strains to second-line
drugs which is the XDR TB [4].
Multidrug-resistant Tuberculosis (MDR TB) is defined as resistance to at least both Isoniazid
and Rifampicin with or without resistance to other first-line drugs. [5]. A subset of this is
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Figure 2. Percentage of previously treated TB cases with MDR-TB (Adapted from WHO Global TB Report, 2014)
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Extensively Drug-Resistant Tuberculosis (XDR TB) where there is also resistance to fluoro‐
quinolones and at least one injectable second-line drug (such as Amikacin, Kanamycin, or
Capreomycin) in addition [6]. XDR TB was first noted in the late 1980s and 1990s and reported
by WHO and Center for Disease Control (CDC), USA, in 2004.
In a survey of some of their National Reference laboratories, it was observed that 20% of
resistant strains tested were MDR TB, while 10% were XDR TB. Asia and Eastern Europe had
the highest rates [7]. From recent reports, about 60% of the global burden of Multidrug-resistant
TB is in China, India and Russia occurring in 3.7% of new TB cases (CI: 2.1-5.2%) and 20% of
previously treated TB cases (CI:13-26%). In countries where there are data available, 9% of
MDR–TB cases have XDR (CI: 6.7-11.2%) and 14.5% have fluoroquinolone resistance (CI:
11.6-17.4%) [8].
According to the WHO, Eastern Europe’s rates of MDR TB are the highest and MDR TB makes
up to 20% of all new TB cases, while in The Union State, it accounts for 28% of new TB cases.
In Africa, reports of MDR TB based on continuous surveillance as in South Africa [9] show
progressively increasing MDR rates despite overall decreasing numbers of TB cases. This is
attributed to improved notification through laboratory surveillance. In developing countries
with limited access to TB drug sensitivity tests, prevalence of MDR TB is dependent on special
national surveys [1] and hospital-based clinical researches as in Nigeria [10-18]. Most of the
hospital-based reports in Nigeria indicate that there is some level of MDR TB, which though
not documented on a regular basis show progressive increase over time. This case scenario
plays out in other developing countries where continuous surveillance or monitoring of MDR
TB is not available. In Nigeria, as well as in other high-burden countries such as South Africa
and India, it has been noted that the increasing TB prevalence may be driven by HIV coinfection
[19]. Most of these reports are, however, based on testing of adult populations.
Pediatric MDR TB has been majorly underreported in continuous surveillance and special
surveys. However, in some countries like South Africa, some modest efforts have been made
to document and monitor progress of disease in these populations. A recent meta-analysis [20]
of WHO data between 1994 and 2011, testing associations between MDR TB and age groups
<15 years, and those >15 years, revealed that MDR TB was positively associated with age
<15years in Germany, Namibia, South Africa, UK, and USA. The data also revealed that similar
proportions of children and adults were diagnosed with MDR TB in many settings. HIV
coinfection was found to be in close association with pediatric MDR TB in South Africa
invariably due to the high prevalence of HIV in this area.
2.1. Genesis of MDR TB
Drug-resistant TB has microbial, clinical, and programmatic causes [21]. It manifests when
there is a selective growth of resistant mutants among the actively multiplying bacillary
population in the presence of drugs, thus making the drug ineffective against mutant bacilli.
Microbiologically, the emergence of drug resistance depends upon the frequency of drug-
resistant mutants in the susceptible bacillary population, the size of the actively multiplying
bacillary population in the lesions, and the antimicrobial quality of the drugs used [22]. The
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frequency of spontaneous mutations that can be developed to each drug are believed to be of
the following magnitude: Streptomycin 1 in 106, Isoniazid 1 in 106, Rifampicin 1 in 108,
Ethambutol 1 in 107, Pyrazinamide 1 in 106, Fluoroquinolones 1 in 106-8 [23]. When these drug-
resistant mutants occur in large bacterial population, they have a tendency to further multiply
depending on the corresponding clinical treatment regimen the patient receives. This varies
from one program to the other and will depend on what drugs are available to a treatment
program and the ease of access the patients have to these drugs.
Administered therapy may be inadequate in the following instances: monotherapy, poor
adherence to treatment protocols, erratic or even interrupted treatment, or low drug quality.
When there is inadequate treatment, resistance develops because bacilli with drug-resistant
mutation proliferate and become the dominant strain in the infected individual. Inadequate
treatment of susceptible TB can lead to drug resistance to first-line drugs (MDR TB), which is
a marker of a failing susceptible TB treatment program. Likewise, inadequate treatment of
MDR TB will lead to drug resistance to second-line drugs (XDR TB), which is a marker of failing
MDR TB treatment programs.
Drug resistance of the Mycobacterium tuberculosis isolated from patients may be categorized
based on length of previous anti-TB drug therapy they had received prior to the diagnosis of
resistance. Acquired drug resistance is described in those who have been inadequately treated
for 1 month or more; Relapse in cases previously completed treatment and reported cured;
while that of patients who have never been treated previously or treated for less than 1 month
is called Primary drug resistance or resistance in new case. The patients grouped as relapse or
as new infections which are found to be drug resistant are grouped together as transmission
cases; 82% of MDR TB are reported to be transmission cases. The other 18% are acquired cases,
which are mostly adult populations. The acquired cases provoke and sustain MDR TB
epidemics in both developed and undeveloped countries [24].
2.2. Epidemics of MDR TB
During the late 1980s and early 1990s, epidemics of MDR TB occurred in North America and
Europe killing about 80% of those who were infected. Today, the greatest number of cases is
in India and China [25-26], although smaller epidemics have been described due to migrations
[27]. The convergence of the following were believed to precipitate MDR TB epidemics
especially that of XDR TB: High TB burden, high HIV prevalence, suboptimal TB control
practices, and introduction of second-line TB drugs into low- and middle-income countries
[28-29]. Among the pediatric age group, there is global paucity of data on MDR TB epidemics.
Most data obtained have been reported from South Africa [30]. Some of the identical issues
that were identified in all these epidemics were that there was delayed diagnosis of MDR TB
cases for over 6 weeks to 6 months due in turn to delayed turnaround time for mycobacterial
culture and DST. This invariably led to very high mortality rates which first called attention
to the need for DST. In the XDR TB epidemic reported in South Africa [29], there was promi‐
nence of associated HIV coinfection in most patients who were transmission cases. Another
feature was poor observance of infection control precautions such as: inadequate patient
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isolation and airflow regulation within wards, which made the wards conducive for trans‐
mission between patients in contact with MDR TB cases. There was also notable direct
transmission from patients to health care workers, which was evident by Tuberculin Skin Test
(TST) conversion as well as later linkage mappings that correlated the strains in the patients’
samples with those of the health workers [29].
2.3. Implications of transmission versus acquired cases
In the high-burden countries, there are reportedly 20-35.2% of new cases and 54-62% of relapse
cases that develop MDR TB, accounting for 82% of all incidences of MDR TB [1]. Thus, high
burdens of MDRTB and XDR TB are eventually perpetuated from direct transmission within
communities. In cases where TB–HIV coinfections are also prevalent, this significantly favors
direct transmissibility [31]. Direct transmission is therefore the most common way drug-
resistant TB is spread and this must be stemmed to arrest the imminent global health threat
from TB.
3. MDR TB diagnosis: Clinical versus laboratory methods
Bacteriological confirmation of TB and Drug sensitivity Testing (DST) of patients presenting
with clinical features of Tuberculosis is targeted as universal standard for patient care in TB
[1]. When this is incorporated into routine clinical care package and results are available for
periodic analysis, it forms a strong database for information about drug resistance in that area.
3.1. Clinical criteria
WHO global TB report [1] revealed that only 2.8 million (58%) of the 4.9 million incident
pulmonary TB patients notified in 2013 were bacteriologically confirmed (smear- or culture-
positive according to a WHO-recommended rapid diagnostic such as Xpert MTB/RIF). The
remaining 42% notifications were diagnosed clinically (symptoms, signs, chest X-ray abnor‐
malities, or suggestive histology). Notifications of new cases are mainly from the high-burden
countries, majority of which are low- and middle-income economies. Their capacity for
confirmatory testing and DST is limited. Although almost half of notified global TB diagnosis
is by clinical methods, this form of diagnosis is attended by poor specificity and false-positive
diagnosis. Low laboratory rates, on the other hand, may suggest underdiagnosis of true TB
cases and contribute to the gap noticed between notified and estimated incident TB cases [1].
The need for skilled health care workers who can make presumptive diagnosis to improve
notification while laboratory methods are being scaled-up, especially in the high-burden
countries cannot be overemphasized.
However, the drawback of clinical criteria alone to make a diagnosis in MDR TB is obvious.
Detection of TB without investigating drug sensitivity potentially can lead to inadequate
treatment and this could lead to spread of MDR TB.
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3.2. Laboratory diagnosis – Screening and confirmatory tools
The field of TB diagnosis has been dynamic, changing constantly with the new challenges
posed by the bacilli: from being fully susceptible to multidrug therapy to the appearance of
MDR TB and now XDR TB. Whereas the need to have accurate bacteriological diagnosis and
appropriate drug sensitivity has not changed, the tools to achieve these have continued to
evolve as newer and hopefully equally or more effective diagnostic technologies are devel‐
oped. Diagnosis of MDR TB requires culture to confirm TB and drug susceptibility testing or
molecular testing. The challenges faced in achieving these include:
• Laboratory challenges with technical capacity, biosafety, cost, slow growth
• Patient challenges in access to adequately testing facilities – communication, transportation
of specimen, and reporting remain critical to success
• Policy challenges in who should be tested and when to test given limited public health
resources
Increasingly, molecular technologies are being incorporated into drug resistance surveys to
simplify logistics. By 2009, the EXPAND –TB (Expanding Access to New Diagnostics for TB)
was launched to accelerate access of MDR TB high-risk populations in high TB burden
countries to sophisticated but rapid diagnostic molecular techniques and provide laboratory
services. The 27 high MDR TB burden countries were equipped with 97 new or refurbished
laboratories and line probe assays (DNA strip test that allows simultaneous molecular
identification of TB and the most common genetic mutations causing resistance to Rifampicin
and Isoniazid) in reference laboratories which can diagnose MDR TB in two days. By December
2010, the WHO issued a policy on the use of another molecular diagnostic test Xpert MTB/RIF
as an initial diagnostic test for cases at risk of MDR TB with negative sputum. The Xpert test,
a cartridge-based automated diagnostic test that can identify Mycobacterium tuberculosis
DNA and resistance to Rifampicin by nucleic acid amplification technique was a sputum only
test for pulmonary TB [32].
A review of WHO policy followed in 2013 that Xpert MTB/RIF should be used rather than
conventional microscopy, culture, and DST as the initial diagnostic test in adults and children
suspected of having MDR TB or HIV associated TB. It may be used for diagnosis of drug-
susceptible TB, smear-negative individuals and cases of extra-pulmonary TB testing using
non-respiratory specimens such as lymph nodes. By the end of June 2014, 108 countries had
benefitted from procurement of Gene Xpert machines. GenoType® MTBDRplus (Hain
Lifescience, Germany) was used in the national survey completed in 2012 in Nigeria and is
currently being used in the national survey in Sudan. In Pakistan, Xpert® MTB/RIF (Cepheid
USA) identified additional cases missed by culture in the national survey completed in 2014.
In ongoing surveys in Papua New Guinea and Senegal, Xpert MTB/RIF is being used to screen
specimens for rifampicin resistance and identify those requiring further testing at national or
supranational TB reference laboratories. Surveys planned in 2014−2015 in Côte d’Ivoire, the
Democratic Republic of the Congo, Indonesia, and Zimbabwe will adopt the same testing
algorithm [1].
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This approach greatly reduces the workload for laboratories and decreases the cost of national
surveys. It may also result in the detection of cases that would otherwise have been missed by
culture and conventional DST, particularly in settings with delays in transporting sputum
samples to laboratories for testing. Although not a complete surrogate for MDR-TB, particu‐
larly in settings where levels of drug resistance are low, rifampicin resistance is the most
important indicator of MDR-TB and has serious clinical implications for affected patients.
It is noteworthy that the supply of these technologically advanced diagnostics though now in
more countries cannot serve the total at-risk populations, because these machines are kept
strategically in reference laboratories. There is a critical need to develop within each country
a framework that would address the accessibility to reference centers. In the Western Pacific
and Eastern Mediterranean regions, it is reported that there was less than one reference center
per 100,000 population. In Nigeria, a high TB burden country and the fourth highest African
country with MDR TB, there are only 9 reference centers which are inadequate for the whole
at-risk population of 170 million.
There is therefore need in the high TB burden areas to still supplement the recent high-tech
diagnostic tools with sputum smear microscopy as an initial screening tool and as such be
placed in such a way that these can be accessible to all. Improvements in microscopy using
fluorescent light emitting diode microscopy, which is more sensitive than light microscopy,
has been proposed and adopted in South Africa, and less so in Mozambique, Bangladesh, and
Nigeria [1].
The other aspect that needs careful attention in laboratory diagnosis is the need for regular
quality assurance of the machines. Likewise, regular capacity training for laboratory personnel
to ensure optimal standards of diagnosis and DST Xpert MT/RIF Newer areas of research for
improved diagnostics is the research for correlates of protective immunity and host biomarkers
of TB that could help determine the potential for susceptibility or protection [33].
4. Unrecognised MDR TB populations
4.1. Pediatric MDR TB
Pediatric TB diagnosis has also been largely based on clinical criteria due to the pauci bacillary
nature of their disease [3, 34-36]. In the cases of TB HIV coinfection, the diagnosis of TB disease
is usually more difficult because the symptom specificity is reduced due to similarity with
chronic HIV-related symptoms, and chest radiograph interpretation is complicated by HIV-
related comorbidity and atypical disease presentation. In this case, diagnosis involves linking
the child with an adult with confirmed pulmonary TB [37]. However, older children producing
sputum can have bacteriological confirmation and where facilities are accessible DST is
performed [8]. To date, there is still widespread under-diagnosis of MDR TB in younger
children. Children are less likely than adults to acquire MDR TB during treatment due to the
lower bacillary load and less-frequent cavity formation [38]. Acquisition of strains of MDR TB
through primary transmission has been shown to be same for children as for adults [39].
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The implication of this is that with increasing adult MDR TB in populations, there would be
increasing incidences of pediatric MDR TB. Once a diagnosis of TB is made, MDR TB should
be carefully considered by review of household source cases for drug-resistant disease [40].
Child contacts of adults with coinfection of TB HIV should particularly be screened for MDR
TB. The recent efforts to improve on MDR diagnostic tests using non-respiratory specimens
should be harnessed for the pediatric age populations so that rapid diagnostic tests become
the first-line diagnostic tool for pediatric MDR TB. Outcomes of MDR TB in children depend
on prompt diagnosis and initiation of appropriate therapy for drug-resistant strain [41].
5. Challenges in MDR TB therapy
The Global target of MDR TB treatment is to achieve 75% treatment success by 2015. To achieve
success in treatment programs, WHO has published a document which contains the guide to
Programmatic Management of Drug-resistant TB (PMDT) which covers all key policies in
MDR TB care and control. The numbers of cases treated are usually reported in cohorts that
commence therapy within a certain year. In this way it is hoped that treatment outcomes would
be clearly understood and modifications where necessary would be implemented. WHO [1]
reports increasing numbers of cases enrolled into treatment programs for MDR TB and XDR
TB of 47% from 2010 to 2013. In specific terms, however, this increase has been achieved mainly
in low TB burden countries. The issue of inadequate notification from weak reporting systems
in most high-burden countries is also thought to contribute to only a modest increase despite
all efforts made at increasing treatment coverage. Notification still plays a crucial part in the
monitoring of treatment outcomes. This depends on systematic record collection, storage, and
retrieval by electronic means. All these processes are not uniformly accessible in all parts of
the same country and also differ significantly from country to country. Adequately trained
personnel to manage this process is crucial and a vital gap.
The treatment target of 75% success outcome has only been reached by 29 out of 126 countries
that have reported outcome. Only five of the 27 MDR TB high-burden countries have reached
70% treatment successes (Figure 3). The success recorded in high-burden countries is closely
related to the implementation of EXPAND TB project and the scale-up of PMDT in these
countries. The identified gaps to achieving treatment include unavailability of second-line TB
drugs whose costs are prohibitive in many high-burden countries. This requires substantial
financial and health care resources [42]. To ameliorate this, the Global Fund facility which
procures TB drugs for the public sector of many countries has increased supply and dropped
prices of some MDR TB drugs by 2009 [43].
5.1. Clinical and laboratory monitoring
Drugs used in the treatment of MDR TB are less effective, more toxic (90% experience side
effects), used for longer duration (usually more than 2 years’ duration), and are more costly
than drugs used in susceptible TB (10-100 times more costly) [44]. In the 27 high-burden
countries, the expenditure for MDR-TB treatment has increased cost of TB care from an
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estimated 1.3 billion USD in 2010 to 4.4 billion USD by 2015 [45]. Some of the common adverse
effects might also require monitoring such as ototoxicity and renal failure. There is also the
need to document improvement by follow-up of bacteriologic cultures. In addition to these,
cases need to be monitored because some MDR TB cases are in advanced stages of disease with
other end-stage organ failures. MDR TB therapy is often characterized by low treatment
completion rates due to death (15%), default (14-23%), and treatment failure (8-9%) [46]. To
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Figure 3. Treatment outcomes for patients diagnosed with MDR TB by WHO region, 2007-2011 cohorts.
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achieve increased access, compliance, effective therapy, and retention in care, there is a need
for close monitoring. This is traditionally done by hospital-based care at MDR TB referral
centers for the initial therapy through health care providers. The model of care involves an
initial hospitalization until sputum culture conversion followed by ambulatory phase of
treatment in the nearest DOTS facility. However, hospital-based care may serve as an obstacle
to access. Ambulatory-based care and community-based care have been proposed in manage‐
ment of MDR TB cases [47]. There have been some successful experiences in some countries
using these methods [1]. There would be need for collaboration between these models of care
especially when dealing with patients with advanced disease who may benefit for some
periods from hospital-based care but would need community- or home-based care for terminal
stages. Community and Ambulatory care also serve to ensure adequate contact tracing for
cases of MDR and XDR TB, which is of great importance given the role of transmission of
disease in spreading the MDR TB epidemic.
When contacts are traced, there is need for DST to identify appropriate second-line drugs.
Currently, the diagnostic tools recommended are molecular-based testings: Line probe Assays
and Xpert MTB/RIF. There is need, however, to establish quality control measures for these
tests to avoid false positives and false negatives. Such tools as would ensure international
standards for reference laboratories and other peripheral centers have been developed in some
countries. Laboratory monitoring also includes structured assessment tools for TB microscopy,
which is shared among laboratory networks.
6. Prevention of MDR TB
To achieve success in the control of MDR TB, there would be a need to strengthen existing TB
DOTS programs. To achieve this, some areas that should be focused on are the creation of
infection control policies both within and outside institutions. Health education of how
transmission of disease occurs from cases to vulnerable groups should be emphasized in
communities. Community-based care should be strengthened with recruitment of staff for
contact tracing of MDR cases, screening of the contacts, treatment administration, and
identification of those who are defaulting on treatment or require institutionalized care. There
should be expansion in the teams with involvement of all relevant health care partners to
strengthen Public–Private Mix initiatives for TB care and control [48-52].
6.1. Infection control
This aims to prevent transmission from cases to other patients or health care workers. The
following means could help to ensure the protection of health care staff: Use of N95 mask by
all staff on medical and TB isolation wards and in the HIV clinics [53]; HIV testing of all staff
with reallocation of those testing positive to lower-risk positions; Annual Chest Xray screening
for TB for all staff [24,54].
Within health care institutions, TB control officers should be hired as well as cough officer in
waiting areas who would identify those that are in hospital for other reasons but who may
Emerging Public Health Issues in Drug-Resistant Tuberculosis
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require TB screening. The duration of hospital admission and stay should be reduced. There
should be environmental airflow control to ensure maximal ventilation (natural mechanical
ventilation within the ward and the use of outdoor waiting areas for outpatients). MDR TB
isolation wards should be created with attention paid to laminar airflow [55].
Infection control programs should be created with plans for intervention should transmission
be proved.
7. Conclusions
Underdiagnoses of MDR TB and XDR TB cases pose significant challenge for TB control. The
current available means for tracking and monitoring are inadequate since they are reliant on
reported data which are usually incomplete. These data overlook transmission to unrecog‐
nized populations which sustain MDR TB epidemics. There is also a need to make diagnostic
tools more available and accessible for cases and contacts and more reference laboratories
provided. These laboratories should be monitored to assure they maintain international
standards and produce reliable results. Once diagnosis has been made promptly and accu‐
rately, adequate therapy for MDR TB should be instituted. This would require clinical
monitoring of cases through collaboration of hospital, community, and ambulatory care
services. Control programs should also target health care givers to prevent transmission of
MDR TB to them from cases. In essence, routine TB DOTS programs should be strengthened
in collaboration with public–private mix initiatives to enhance MDR TB control.
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